Next generation antibody drugs: pursuit of the 'high-hanging fruit'

By P. Carter, G. A. Lazar. Nature reviews. Drug discovery, 2017

704 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cytokine release syndrome (2018, background): “These include dual-affinity retargeting antibodies (DART), immune-mobilising monoclonal TCRs against cancer (ImmTAC), and other TCRbased strategies [20, 21].”
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials (2020, background): “It was approved to be marketed in 2016 for the treatment of chronic lymphoblastic leukemia.(89) By studying the complex structure of Bcl-2 protein and small molecule acyl sulfonamide compounds, it was found that the introduction of indole group was beneficial to enhance the binding of drugs to P4 po”